Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Ferreri CJ, et al. Among authors: dima d. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8. Blood Cancer J. 2023. PMID: 37558706 Free PMC article.
Multiple Myeloma Therapy: Emerging Trends and Challenges.
Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, Khouri J, Maciejewski JP, Jha BK. Dima D, et al. Cancers (Basel). 2022 Aug 23;14(17):4082. doi: 10.3390/cancers14174082. Cancers (Basel). 2022. PMID: 36077618 Free PMC article. Review.
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Hansen DK, et al. Among authors: dima d. J Clin Oncol. 2023 Apr 10;41(11):2087-2097. doi: 10.1200/JCO.22.01365. Epub 2023 Jan 9. J Clin Oncol. 2023. PMID: 36623248 Free PMC article.
On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone.
Hubben A, Dima D, Atieh T, Chaulagain C, Faiman B, Ferraro C, Mazzoni S, Williams L, Samaras C, Valent J, Sauter C, Anwer F, Khouri J. Hubben A, et al. Among authors: dima d. Bone Marrow Transplant. 2023 May;58(5):610-612. doi: 10.1038/s41409-023-01938-0. Epub 2023 Feb 24. Bone Marrow Transplant. 2023. PMID: 36828957 Free PMC article. No abstract available.
Daratumumab monotherapy for relapsed POEMS syndrome.
Dima D, Valent J, Khouri J. Dima D, et al. Am J Hematol. 2023 Nov;98(11):E291-E294. doi: 10.1002/ajh.27050. Epub 2023 Aug 7. Am J Hematol. 2023. PMID: 37548551 Free article. No abstract available.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Sidana S, et al. Among authors: dima d. Haematologica. 2024 Mar 1;109(3):777-786. doi: 10.3324/haematol.2023.283940. Haematologica. 2024. PMID: 37731379 Free PMC article.
256 results